Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2010 Jul 20

PMID 20640233

Citations 25

Authors

Matthew D Krasowski

Affiliations

Soon will be listed here.

Abstract

In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not been established in clinical trials for these new anticonvulsants, and clear guidelines for drug monitoring have yet to be defined. The antiepileptic drugs with the strongest justifications for drug monitoring are lamotrigine, oxcarbazepine, stiripentol, and zonisamide. Stiripentol and tiagabine are strongly protein bound and are candidates for free drug monitoring. Therapeutic drug monitoring has lower utility for gabapentin, pregabalin, and vigabatrin. Measurement of salivary drug concentrations has potential utility for therapeutic drug monitoring of lamotrigine, levetiracetam, and topiramate. Therapeutic drug monitoring of the new antiepileptic drugs will be discussed in managing patients with epilepsy.

Citing Articles

Serum perampanel levels in patients with seizures are not affected by hemodialysis.

Nakazawa Y, Shiraishi W, Matsuyoshi A, Inamori Y, Mitani K, Ando N Epilepsia Open. 2024; 9(4):1597-1603.

PMID: 38923803 PMC: 11296135. DOI: 10.1002/epi4.12996.

Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.

Maglalang P, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik C Clin Pharmacokinet. 2024; 63(6):885-899.

PMID: 38814425 PMC: 11225543. DOI: 10.1007/s40262-024-01367-2.

Topiramate dosage optimization for effective antiseizure management via population pharmacokinetic modeling.

Lee S, Kim H, Jang Y, Lee H, Ahn S, Lee S Ann Clin Transl Neurol. 2023; 11(2):424-435.

PMID: 38062636 PMC: 10863906. DOI: 10.1002/acn3.51962.

Initial therapeutic target attainment of perampanel in pediatric patients with epilepsy.

Yu L, Chen M, Liu J, Yu Z, Feng J, Dai H Front Pharmacol. 2023; 14:1209815.

PMID: 38035012 PMC: 10684762. DOI: 10.3389/fphar.2023.1209815.

Lacosamide dosing in patients receiving continuous renal replacement therapy.

Chaijamorn W, Phunpon S, Sathienluckana T, Charoensareerat T, Pattharachayakul S, Rungkitwattanakul D J Intensive Care. 2023; 11(1):50.

PMID: 37946296 PMC: 10633951. DOI: 10.1186/s40560-023-00700-4.

References

Tsiropoulos I, Kristensen O, Klitgaard N . Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit. 2000; 22(5):517-21. DOI: 10.1097/00007691-200010000-00003. View

Mimrod D, Specchio L, Britzi M, Perucca E, Specchio N, La Neve A . A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia. 2005; 46(7):1046-54. DOI: 10.1111/j.1528-1167.2005.06805.x. View

Poquette M . Isothermal gas chromatographic method for the rapid determination of felbamate concentration in human serum. Ther Drug Monit. 1995; 17(2):168-73. DOI: 10.1097/00007691-199504000-00011. View

Tran A, Rey E, Pons G, Rousseau M, dAthis P, Olive G . Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997; 62(5):490-504. DOI: 10.1016/S0009-9236(97)90044-8. View

Contin M, Mohamed S, Candela C, Albani F, Riva R, Baruzzi A . Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 878(3-4):461-5. DOI: 10.1016/j.jchromb.2009.11.039. View

Chollet D, Castella E, Goumaz L, Anderegg G . Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. J Pharm Biomed Anal. 2000; 21(3):641-6. DOI: 10.1016/s0731-7085(99)00167-3. View

Von Unruh G, Paar W . Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol. Biomed Environ Mass Spectrom. 1986; 13(12):651-6. DOI: 10.1002/bms.1200131203. View

Pucci V, Bugamelli F, Baccini C, Raggi M . Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography. Electrophoresis. 2005; 26(4-5):935-942. DOI: 10.1002/elps.200410208. View

Jones M, Ryan M, Miles M, Tang P, Fakhoury T, DeGrauw T . Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit. 2005; 27(5):576-9. DOI: 10.1097/01.ftd.0000171869.56817.ae. View

10.

Glauser T, Pippenger C . Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia. 2000; 41 Suppl 8:S6-15. DOI: 10.1111/j.1528-1157.2000.tb02950.x. View

11.

Lloyd P, Flesch G, Dieterle W . Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994; 35 Suppl 3:S10-3. DOI: 10.1111/j.1528-1157.1994.tb05938.x. View

12.

Faught E, Sachdeo R, Remler M, Chayasirisobhon S, Iragui-Madoz V, Ramsay R . Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology. 1993; 43(4):688-92. DOI: 10.1212/wnl.43.4.688. View

13.

Nakamura M, Hirade K, Sugiyama T, Katagiri Y . High-performance liquid chromatographic assay of zonisamide in human plasma using a non-porous silica column. J Chromatogr B Biomed Sci Appl. 2001; 755(1-2):337-41. DOI: 10.1016/s0378-4347(01)00062-7. View

14.

Leppik I . The place of levetiracetam in the treatment of epilepsy. Epilepsia. 2001; 42 Suppl 4:44-5. View

15.

Lee W, Kim J, Kim H, Kwon O, Lee B, Heo K . Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry. Neurol Sci. 2010; 31(6):717-20. DOI: 10.1007/s10072-010-0257-x. View

16.

Bialer M . The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther Drug Monit. 2006; 27(6):722-6. DOI: 10.1097/01.ftd.0000179854.16846.67. View

17.

Beck O, Ohman I, Nordgren H . Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther Drug Monit. 2006; 28(5):603-7. DOI: 10.1097/01.ftd.0000245779.64080.30. View

18.

Berent S, Sackellares J, Giordani B, Wagner J, Donofrio P, Abou-Khalil B . Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia. 1987; 28(1):61-7. DOI: 10.1111/j.1528-1157.1987.tb03624.x. View

19.

Popova E, Leighton C, Bernabarre A, Bernardo M, Vieta E . Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother. 2007; 7(6):617-26. DOI: 10.1586/14737175.7.6.617. View

20.

Britzi M, Soback S, Isoherranen N, Levy R, Perucca E, Doose D . Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit. 2003; 25(3):314-22. DOI: 10.1097/00007691-200306000-00012. View